Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Impel NeuroPharma is targeting the migraine market

The company aims to reestablish DHE as a cornerstone of acute migraine treatment.

By Brian Buntz | September 21, 2021

Impel Neuropharma

(PRNewsfoto/Impel NeuroPharma)

The analgesic dihydroergotamine (DHE) has perhaps the longest track record of any effective migraine medicine.

Seattle-based Impel NeuroPharma (NSDQ:IMPL) aims to reestablish DHE as a cornerstone of acute migraine treatment following the FDA approval of Trudhesa, a DHE nasal spray. Trudhesa uses the company’s Precision Olfactory Delivery (POD) that delivers the drug to the vasculature within the upper nasal cavity.

“I’ve been in this field for 30 years. I still have the privilege of seeing patients, and nothing in the realm of new treatments has quite met that need that DHE fulfills,” said Dr. Sheena K. Aurora, vice president of medical affairs, migraine at Impel NeuroPharma. DHE continues to offer compelling efficacy for, say, patients who wake up in the morning with a migraine and patients with menstrually-associated migraine.

Dr. Sheena K. Aurora

Dr. Sheena K. Aurora

While DHE is currently available as a nasal spray, there are problems with the repeatability when delivering the drug to the lower nasal cavity, said Adrian Adams, chairman and CEO of Impel NeuroPharma. Conversely, delivery to the upper nasal cavity avoids the pitfalls of delivering “to the lower nasal space, where you can get dripping down the back of the throat,” Adams explained. “You can, in essence, swallow efficacy.”

Impel NeuroPharma said its proprietary intranasal delivery method of DHE offers pharmacokinetics similar to IV-based delivery. It does so, however, without the nausea and vomiting sometimes associated with that delivery route.

The migraine treatment landscape has matured in recent years, but many patients remain frustrated. “Most migraine patients pass through triptans,” Adams said, referring to the drug class that became a popular migraine treatment beginning in the 1990s. “But a very significant proportion of patients either do not tolerate it or just don’t get the efficacy. So, we refer to them as triptan failures.”

Adrian Adams

Adrian Adams

Similarly, gepants, small molecule calcitonin gene-related peptide (CGRP) receptor antagonists, have also grown in popularity. Notable treatments include Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant). “Gepants represent most of the growth within the market at this particular point in time,” Adams said. “But despite this, almost half of the patients who are put on those treatments either switch away or drop off therapy. And the reason for that predominantly is related to disappointments in efficacy or issues related to the broader aspects of tolerance, particularly GI issues, etc.”

While it is challenging to compare the performance of migraine treatments, gepants don’t seem to match the efficacy of triptans, Aurora said. “Patients never know if they’re going to respond to [gepants], and they’re really haven’t been a lot of consistency studies.”

“So, even though there’s been a lot of development in the acute treatment of migraine, nothing really has filled the shoes of the efficacy of DHE,” Aurora said.

“While DHE has been around for many, many years, and is recognized as being a gold standard efficacy product, the challenge has been that it was tough to deliver that gold standard efficacy in a predictable, consistent way,” Adams said. “So by combining DHE with our [POD drug delivery] technology gave that precise delivery.”

In addition to Trudhesa nasal spray, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for off episodes in Parkinson’s disease.


Filed Under: Neurological Disease
Tagged With: DHE, dihydroergotamine, Impel NeuroPharma, migraine, migraine headaches, migraines
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE